Evolocumab 120 mg/ML [Repatha]
RxNorm 1801320

Concept Hierarchy & Relationship Mapping

RxNorm Concept Unique Identifier (RxCUI) 1801320 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: evolocumab 120 mg/ML [Repatha].

The following semantic concepts and normalized strings are associated with this clinical entity:

SBDC
Evolocumab 120 mg/ML [Repatha]
AUI:8237694

This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.

SBDCPrescribable

Semantic Branded Drug Component (SBDC):
Evolocumab 120 mg/ML [Repatha]
(Atom ID: 8237694)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
evolocumab 120 MG/ML [Repatha]
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
1801320
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
8237694
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
SBDC
Semantic Branded Drug Component (Ingredient + Strength + Brand Name)
Source Code
1801320
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.

Patient Education

Evolocumab Injection


Evolocumab injection is used to reduce the risk of a stroke or heart attack or the need for coronary artery bypass (CABG) surgery in people with cardiovascular disease. Evolocumab injection is also used along with diet alone or in combination with other cholesterol-lowering medications such as HMG-CoA reductase inhibitors (statins) or ezetimbe (Zetia) to decrease the amount of low-density lipoprotein (LDL) cholesterol ('bad cholesterol') in the blood, including people who have familial heterozygous hypercholesterolemia (HeFH; an inherited condition in which cholesterol cannot be removed from the body normally). It is also used along with diet changes and other treatments to reduce the amount low-density lipoprotein (LDL) cholesterol ('bad cholesterol')in the blood in people that have homozygous familial hypercholesterolemia (HoFH; an inherited condition in which cholesterol cannot be removed from the body normally). Evolocumab injection is in a class of medications called proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor monoclonal antibody. It works by blocking the production of LDL cholesterol in the body to decrease the amount of cholesterol that may build up on the walls of the arteries and block blood flow to the heart, brain, and other parts of the body. Accumulation of cholesterol along the walls of your arteries (a process known as atherosclerosis) decreases blood flow and, therefore, the oxygen supply to your heart, brain, and other parts of your body.
[Learn More]


* Please review the disclaimer below.